News

Date
Title
Sort By:
09/01/26
SCYNEXIS to Participate in Upcoming Investor Conferences
08/25/26
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
08/10/26
SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
06/30/26
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
05/22/26
SCYNEXIS Announces One-for-Eight Reverse Stock Split
05/11/26
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
05/07/26
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03/31/26
SCYNEXIS Announces $40.0 Million Private Placement
03/31/26
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
03/04/26
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update